|
**Overview**: Wilson Disease Panel**Introduction**: The Wilson Disease Panel is a diagnostic tool designed for Wilson disease screening using serum samples. In India, Wilson disease (ATP7B mutation) has a prevalence ~1 in 30,000-50,000, causing copper accumulation with hepatic failure, neurological symptoms, or Kayser-Fleischer rings in young adults/children. High morbidity from under-testing in rural/low-SES patients with unexplained liver disease, tremor, or psychiatric symptoms, limited metabolic labs, delayed chelation (penicillamine/zinc) leading to irreversible cirrhosis or neurological damage. Per hepatology practices aligned with ICMR and Indian National Association for Study of the Liver guidelines, the test employs spectrophotometry/immunoassay for 37 parameters (ceruloplasmin, serum/urine copper, liver enzymes, bilirubin, proteins, hematology, etc.) over 1â€"2 days with high accuracy, valuable for diagnosing low ceruloplasmin (<20 mg/dL) and high free copper. This diagnostic falls under metabolic screening and targets patients with liver/neurological symptoms or family history, addressing accurate detection to guide chelation and copper diet. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling comprehensive Wilson profiling and reducing fatal outcomes. Its serum-based approach ensures reliable multi-parameter evaluation.**Other Names**: Wilson Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/clinical pathology, compliant with 2025 standards.**Historical Milestone**: Ceruloplasmin + copper panel standard in Wilson diagnosis; in India, expanding in liver clinics.**Purpose**: The test assesses 37 parameters including ceruloplasmin to guide Wilson disease screening, detect copper accumulation, inform chelation.**Test Parameters**: 1. Ceruloplasmin, 2. Serum Copper, 3. Free Copper, 4. Total Protein, 5. Albumin, 6. ALT, 7. AST, 8. ALP, 9. Bilirubin Total, 10. Bilirubin Direct, 11. GGT, 12. Urea, 13. Creatinine, 14. Sodium, 15. Potassium, 16. Chloride, 17. Urine Copper, 18. 24-Hour Urine Copper, 19. Hemoglobin, 20. RBC Count, 21. WBC Count, 22. Platelet Count, 23. PCV, 24. MCV, 25. MCH, 26. MCHC, 27. ESR, 28. Iron, 29. TIBC, 30. Ferritin, 31. Calcium, 32. Magnesium, 33. Phosphorus, 34. Uric Acid, 35. Blood Group, 36. ANA, 37. Anti-dsDNA.**Pretest Condition**: No fasting required; patients should have liver/neurological symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on jaundice, tremor, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected Wilson including liver failure, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry/immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1â€"2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Low ceruloplasmin + high urine copper indicates Wilson disease, necessitating specialist input.**Specialist Consultation**: Hepatologists should be consulted for management.**Additional Supporting Tests**: Slit-lamp for KF rings, ATP7B sequencing for confirmation.**Test Limitations**: Overlap with other liver diseases; comprehensive approach required.**References**: Indian Journal of Gastroenterology 2024, Wilson Studies India 2023. |
